Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide and dexamethasone for resistant multiple myeloma.

Athanasios Anagnostopoulos1, Donna Weber, Kim Rankin

  • 1University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

British Journal of Haematology
|June 5, 2003
PubMed
Summary

The combination of thalidomide and dexamethasone showed a 47% remission rate in multiple myeloma patients resistant to prior therapies. This treatment approach is promising for resistant myeloma and warrants further investigation in newly diagnosed cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.

Journal of the National Comprehensive Cancer Network : JNCCN·2022
Same author

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma.

Haematologica·2021
Same author

Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up.

Blood cancer journal·2021
Same author

Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2020
Same author

New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity.

Haematologica·2020
Same author

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.

Journal of the National Comprehensive Cancer Network : JNCCN·2019

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma is a hematologic malignancy characterized by uncontrolled plasma cell growth.
  • Dexamethasone-based therapies are standard, but drug resistance is a significant clinical challenge.
  • Novel therapeutic strategies are needed for patients with relapsed or refractory multiple myeloma.

Purpose of the Study:

  • To evaluate the efficacy and safety of combining thalidomide with dexamethasone.
  • To assess treatment outcomes in patients with multiple myeloma resistant to prior dexamethasone-based therapies.

Main Methods:

  • A cohort of 47 consecutive multiple myeloma patients with dexamethasone-resistant disease was treated.
  • The treatment regimen involved the combination of thalidomide and dexamethasone.

Related Experiment Videos

  • Patient responses, remission status, and adverse events were monitored.

    • Main Results:

    • An overall remission rate of 47% was observed, with 6 patients achieving complete remission.
    • Side effects were generally mild and reversible, though deep vein thrombosis occurred in 8% of patients.
    • Longer survival and remission times were noted in patients treated for primary resistant disease compared to resistant relapse.

    Conclusions:

    • The combination of thalidomide and dexamethasone demonstrates significant efficacy in multiple myeloma patients with resistant disease.
    • This therapeutic approach is a viable option for managing resistant multiple myeloma.
    • Further clinical trials are warranted to explore this combination in newly diagnosed multiple myeloma patients.